Lewis R Silverman

Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

E. Reddy, S. Baker, Shashidhar S Jatiani, 2010, Genes & cancer.

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

J. Holland, R. Larson, C. Decastro, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.